Filing Signals

Source: SEC EDGAR Compiled 2026-11-14 10:32 UTC 23 automated checks passing

← All events

Annovis Bio, Inc.

CIK 1477845 ANVS·Pharmaceutical Preparations · All EDGAR filings ↗

Progression

  1. SEC comment letter UPLOAD
  2. Going concern 10-Q +262d
Refine
Form
An amendment is grouped with the report it amends; every 12b-25 notice is one group

Going concern Filing comparison

Annovis Bio, Inc. no longer reports substantial doubt about going concern

Substantial doubt about ability to continue as a going concern → No substantial-doubt conclusion identified

The Company follows the provisions of Financial Accounting Standards Board, or FASB, Accounting Standards Codification, or ASC, Topic 205-40, Presentation of Financial Statements-Going Concern, or ASC 205-40, which requires Management to assess the Company’s ability to continue as a going concern for one year after the date its financial statements are issued. The Company expects that its existing balance of cash and cash equivalents, as of September 30, 2026, is not sufficient to fund operations for the period through one year after the date of this filing and therefore, Management has…
Evidence
Blank check
No
Comparable
Yes
Current state
none
Current state label
No substantial-doubt conclusion identified
Direction
eased
Located in
going-concern note
Prior filed
2026-08-14
Prior form
10-Q
Prior state
substantial_doubt
Prior state label
Substantial doubt about ability to continue as a going concern
Source
ASC 205-40 going-concern note comparison
Why
Disclosure about the company's ability to continue as a going concern changed compared with its previous report.
SEC comment letter SEC correspondence

SEC staff questioned Annovis Bio, Inc.'s accounting for MD&A

Letter dated 2025-09-04; published on EDGAR 2026-02-24 — the SEC releases comment letters only after the review closes.

We note your statement on page 82 that you "track and record information regarding external research and development expenses for each study or trial that we conduct." However, you have not provided such a breakout on page 83, nor have you quantified, in the accompanying explanation, the changes in the several factors identified as having contributed to the consolidated change. Given research and development (R&D)…
Evidence
Direction
staff to company
Letter dated
2025-09-04
Published on edgar
2026-02-24
Reviewing
Annovis Bio, Inc. Form 10-K for the fiscal year ended December 31, 2024 Filed March 21, 2025 File No. 001-39202 Dear Maria Maccecchini: We have limited our revi
Source
SEC staff comment letter (UPLOAD)
Topics
MD&A
Why
SEC staff reviewed the company's periodic report and raised written comments on its accounting, or the company replied to them. Letters are published on EDGAR only after the review closes.